Voyager Therapeutics

United States
Primghar, Iowa, United States, 02139

Company profile

Voyager Therapeutics company profile

Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Business identity

Contact email
[email protected]
Phone number
857-259-5340
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2014-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$374M
Last funding
Post IPO Equity / $100M / 2024-01-04
Last equity funding
Post IPO Equity / $100M
Investors
9
Lead investors
6
Founders
4
Articles
263
Exited on
2015-11-11

Founders and investors

Founders

Guangping GaoKrystof BankiewiczMark KayPhillip D. Zamore

Lead investors

Brookside CapitalFidelityGenzymeNeurocrine BiosciencesPartner Fund ManagementThird Rock Ventures

Investors

Casdin CapitalDeerfieldFidelityThird Rock VenturesWellington Management